Antidepressant use during pregnancy and the risk of gestational diabetes mellitus: a nested case–control study

Maëlle Dandjinou,1,2 Odile Sheehy,1 Anick Bérard1,2

ABSTRACT

Objectives The aim of this study was to determine the association between antidepressant (AD) classes, types and duration of use during pregnancy and the risk of gestational diabetes mellitus (GDM).

Design and setting A nested case–control study was conducted within the Quebec Pregnancy Cohort (QPC), a Canadian provincial database which includes data on all pregnancies and children in Quebec from January 1998 to December 2015.

Primary outcome measures Gestational diabetes mellitus.

Participants Cases of GDM were identified after week 20 of pregnancy and randomly matched 1:10 to controls on gestational age at index date (ie, calendar date of GDM) and year of pregnancy. AD exposure was assessed by filled prescriptions between the beginning of pregnancy (first day of last menstrual period) and index date. Conditional logistic regression models were used to estimate crude and adjusted odds ratios (aOR).

Results Among 209,050 cases and 2,090,500 matched controls, 9,741 (4.2%) women were exposed to ADs. When adjusting for potential confounders, AD use was associated with an increased risk of GDM (aOR 1.19, 95% CI 1.08 to 1.30); venlafaxine (aOR 1.27, 95% CI 1.09 to 1.49) and amitriptyline (aOR 1.52, 95% CI 1.25 to 1.84) were also associated with an increased risk of GDM. Moreover, the risk of GDM was increased with longer duration of AD use, specifically for serotonin norepinephrine reuptake inhibitors, tricyclic ADs and combined use of two AD classes. No statistically significant association was observed for selective serotonin reuptake inhibitors. Conclusion The findings suggest that ADs—and specifically venlafaxine and amitriptyline—were associated with an increased risk of GDM.

INTRODUCTION

Gestational diabetes mellitus (GDM), defined as a carbohydrate intolerance occurring during pregnancy, diagnosed between 24 weeks and 28 weeks of pregnancy, is a major maternal health condition.1 2 Studies report that 1–20% of pregnant women are affected by GDM worldwide, depending on the population studied and the diagnostic criteria adopted (International Association of Diabetes and Pregnancy Study Groups (IADPSG) criteria or WHO), and around 7–9% of pregnant women are affected in Quebec.3–6 Moreover, the number is rising concomitantly with the surge in overweight and obesity.7 Pregnancies with GDM are at higher risk of birth complications (eg, macrosomia, caesarean and dystocia) and may predispose offspring to type 2 diabetes and obesity.8–10 Furthermore, mothers with a history of GDM are more likely to develop type 2 diabetes and cardiovascular diseases later in life.11

Antidepressants (ADs) are commonly used during pregnancy and neurotransmitters such as serotonin, norepinephrine and dopamine are the mainstay of their action.12 ADs have several side effects and some of them increase weight.13 There is mounting evidence suggesting that AD classes might be involved in different ways in biological mechanisms such as weight gain, insulin resistance and glucose metabolism dysregulation to induce diabetes.14–17 Moreover, both depression and overweight/obesity are prevalent among women of reproductive age.7 18 Discrepant findings have been reported regarding the relationship between depression and body mass index (BMI).
Some previous studies reported no association, but a meta-analysis reported a possible bidirectional relationship. Depression may increase weight gain and obesity through changes in eating patterns or reduced physical activity and biological mechanisms involving neuroendocrine disturbances could explain the association. Nevertheless, a recent study showed that antenatal depression was not associated with inadequate and excessive gestational weight gain during pregnancy. As maternal depression could possibly increase weight gain and GDM, the potential confounding effect of underlying maternal depression should be addressed in studies assessing the relationship between AD use during pregnancy and GDM. Confounding can be controlled at the study design stage (restriction, matching or randomisation) or at the statistical analysis stage (multivariable models).

Two studies in pregnant women have investigated the association between AD use and GDM, but the evidence was inconclusive and some methodological limitations were not considered such as the non-adjustment for maternal depression. The first study found that AD use was associated with an increase in the risk of GDM whereas the second showed no association with selective serotonin reuptake inhibitors (SSRIs). The two studies lack information about timing of the GDM diagnosis, and confounding by indication related to maternal depression is possible. The small sample size in both studies did not allow individual drug effects to be considered. Given the increasing use of ADs during pregnancy, the biological evidence and the scarcity of information on the associated risk of GDM, this question urgently needs to be addressed. To our knowledge, no study to date has been designed to explore directly the association between AD use and the incidence of GDM in pregnancy.

We therefore assessed the impact of overall AD medication, classes and types, as well as duration of AD exposure on the risk of GDM in a population-based study of pregnant women.

METHODS

Patient and public involvement

Patients or the public were not involved in the design of the study.

Source population

A nested case–control study was conducted within the Quebec Pregnancy Cohort (QPC). The QPC is an ongoing population-based cohort with prospective data collection on all pregnancies insured by the Quebec Public Prescription Drug Insurance Plan, from 1998 to 2015. Individual-level information was obtained from province-wide databases and linked using healthcare unique personal identifiers.

The QPC was established by identifying all pregnancies in the Régie de l’assurance maladie du Québec (RAMQ) and the Quebec hospitalisation archives (MedEcho) databases. The first day of the last menstrual period (first day of gestation, 1DG) was defined using data on gestational age, which was validated against ultrasound measurements in patient charts. Prospective follow-up was available from 1 year prior to 1DG, during pregnancy and until December 2015.

Data sources for this study comprised the medical service database (RAMQ: diagnoses and medical procedures), the Quebec Prescription Drug Insurance Database (drug name, start date, dosage and duration), the Hospitalisation Archive Database (MedEcho: in-hospital diagnoses and procedures) and the Quebec Statistics Database (Institut de la statistique du Québec (ISQ): patient sociodemographic information). Descriptive information regarding the QPC is shown in the paper by Bérard and Sheehy. Validity studies were performed and confirm the accuracy and high quality of the data sources.

The study was approved by the Sainte-Justine’s Hospital Ethics Committee. The Quebec Commission d’accès à l’information authorised database linkages.

Study cohort definition and study design

All women in the QPC continuously covered by the public prescription drug plan for at least 6 months before and during pregnancy were eligible. Given that GDM occurs after week 20 of gestation, we excluded abortions and miscarriages. We only included singleton pregnancies as multiple pregnancies are a known risk factor of GDM. Women with type 1 and type 2 diabetes were identified between 6 months before pregnancy and up to week 20 of gestation, and were excluded because they are at risk of GDM and because overt diabetes is often diagnosed early in pregnancy. Similarly, women with a history of GDM have different metabolic profiles and a different baseline risk of GDM compared with women with no history of GDM, and were thus also excluded from the main analysis. This enabled us to quantify the incident risk of GDM for women without a history of GDM. Studies have reported that women with a history of GDM have a faster deterioration in insulin sensitivity and a lower beta cell compensation which continues to deteriorate after pregnancy.

In order to select a homogeneous population at risk of GDM, we also excluded pregnancies in women with cystic fibrosis as well as those who were overweight (body mass index (BMI) >25 kg/m²) or obese (BMI >30 kg/m²). Women with cystic fibrosis and overweight or obese women are more likely to develop GDM. Hence, women with obesity and cystic fibrosis have been consistently excluded in previous studies with GDM as outcome. Women with cystic fibrosis are more likely to have pre-pregnancy diabetes and pre-pregnancy obesity, which are risk factors for GDM. We excluded those women with either obesity or cystic fibrosis in order to have a homogenous population with regard to these risk factors and to allow comparisons with previous studies.

All pregnancies meeting our inclusion criteria during the study period were considered. Moreover, due to the
time-varying nature of AD use during pregnancy, using a nested case–control analysis was appropriate. As well as a time-dependent survival analysis, this method takes into account time-varying exposure but has the ultimate advantage of being computationally more efficient and providing ORs that are unbiased estimators of rate ratios.

Definition of GDM cases
Cases of GDM were defined as pregnant women with a diagnosis of GDM identified using diagnosis codes of the 9th or 10th editions of the International Classification of Diseases (ICD-9: 250.0–250.9, 648.0, 648.8, 790.2, 775.1 or ICD-10: E10–E14, O24, R73.0) or at least one filled prescription for an antidiabetic drug allowed during pregnancy (insulin, glyburide or metformin), both after week 20 of gestation, whichever occurred first (online supplementary table S1).

This definition was used to identify the earliest calendar date of GDM occurrence (EDI). This definition of the outcome was previously used and GDM ICD codes have been associated with high positive and negative predictive values (PPV: 85% and NPV: 99%). According to the current guidelines in Canada, GDM is diagnosed between weeks 24 and 28 of gestation. In our study we included a lag time of 3 weeks to capture late diagnoses of GDM. If the EDI was between week 20 and week 31 of gestation, the calendar date of the diagnosis of GDM or of a prescription of antidiabetic drug was used as the index date. In other cases, when EDI was recorded after week 31 of gestation, we developed an algorithm which determined the index date by adding 217 days (equivalent to 31 weeks of gestation) to the first day of gestation. This algorithm was used to ensure that all cases were included in the study. Indeed, we hypothesised that EDI could be recorded even after 31 weeks of gestation for several reasons. First, it is possible that a pregnant woman was diagnosed with mild GDM before 31 weeks of gestation and received a prescription of an antidiabetic drug later as her diabetes was controlled with non-pharmacological measures. Second, a woman could also be diagnosed with GDM in her medical visit that was not recorded before 31 weeks of gestation because it was not the most serious medical condition at that moment.

Control selection
Using the nested case–control design and with the low prevalence of exposure to AD among controls (4.1%), we randomly selected 10 controls for each case among those in the risk set (ie, pregnancy that did not have a diagnosis of GDM at the index date) and matched them by gestational age at index date (ie, calendar date of GDM) and year of pregnancy. As a woman could contribute with repeated pregnancies during the study period, cases and controls were matched on the year of pregnancy.

Antidepressant exposure
Gestational AD use was assessed using the RAMQ Prescription Drug file. Data on AD prescription fillings have been validated against maternal reports within the study population and have a high predictive value (PPV 100% and NPV 96%).

Overall antidepressant exposure
Overall AD exposure was identified as having at least one filled prescription from 1DG to index date. Prescriptions filled before the pregnancy and with a duration which included the 1DG were also considered. The overall AD exposure category was compared with the reference category: no AD exposure during the same period (see online supplementary table S2 for codes of all ADs evaluated).

Antidepressant exposure by drug class
We considered AD exposure by class and formed six mutually exclusive comparison groups: (1) selective serotonin reuptake inhibitors (SSRIs), (2) serotonin norepinephrine reuptake inhibitors (SNRIs), (3) tricyclic ADs (TCAs), (4) others (this category includes all the other ADs used). Pregnancies exposed to at least two classes of AD were classified as (5) combined. No AD exposure during the relevant period of time was classified as (6) the reference category.

Antidepressant exposure by drug types
The following nine active categories were studied: (1) citalopram, (2) fluoxetine, (3) fluvoxamine, (4) paroxetine, (5) sertraline, (6) venlafaxine, (7) amitriptyline and (8) others (this category includes all the other ADs used). Pregnancies exposed to more than one AD were classified as (9) combined. No AD exposure (10) between the 1DG and index date was the reference category. The 10 categories were mutually exclusive.

Antidepressant duration of exposure
Finally, we looked at the duration of exposure to AD during pregnancy by adding the length of the filled prescriptions in order to calculate the exact number of days covered by the prescriptions. For pregnancies with a combined use of two or more ADs, if the two ADs had the same overlap, only one exposure time was considered. However, if the duration for the two ADs was not completely overlapping, the additional days of both ADs were added to the overlapping time. Consequently, four mutually exclusive categories were defined: (1) short duration (<90 days of AD exposure), (2) medium duration (90 days<AD exposure<180 days), (3) long duration (≥180 days of AD exposure). The reference category was (4) no exposure to AD in the relevant time period. We also looked at duration of exposure within each AD class.

Covariates
Potential confounders considered for all analyses were (1) sociodemographic variables and maternal characteristics on the 1DG including maternal age, receipt of social assistance (yes/no) and area of residence (urban/rural); (2) maternal chronic comorbidities in the 6 months prior to the pregnancy (physician-based diagnoses or filled prescriptions of related medications for chronic
comorbidities (depression/anxiety, chronic hypertension, asthma and thyroid disorders); physician-based diagnoses of cardiovascular diseases and polycystic ovarian syndrome); (3) healthcare services utilisation and co-medication (physician visits, hospitalisations or emergency department visits, number of other medications used other than ADs and medications related to chronic comorbidities (antipsychotics, benzodiazepines and corticosteroids are included), visits to a psychiatrist within the 6 months prior to pregnancy). All the previous conditions were identified from either diagnoses or disease-specific medications available in our databases (see online supplementary table S3).

**Statistical analysis**

Descriptive analyses (t-tests and $\chi^2$ tests for continuous and categorical variables, respectively) were performed to describe the study population. Crude and adjusted ORs and 95% CIs using conditional logistic regression models were calculated. We considered all analyses significant at a p value $<$0.05 (two-tailed). We conducted all analyses using SAS version 9.3 software (SAS Institute Inc).

Additionally, the following sensitivity analyses were performed:

1. We restricted the study population to women with depression/anxiety prior to pregnancy as identified by either a diagnosis code for depression or anxiety or an AD prescription within 6 months before the 1DG. For women with both a diagnosis code and AD use in the 6 months before the 1DG, only one occurrence was taken into account. This method allowed us to take into account potential confounding by indication.

2. According to the guidelines, GDM is diagnosed between 24 and 28 weeks of gestation; therefore, we looked at diagnoses of GDM strictly between week 24 and week 28. This will minimise a potential non-differential bias that would underestimate the true estimate.

3. We looked at the exposure within the window from the 1DG to 15 days before the index date in order to ensure that the exposure preceded the outcome.

4. As women with a history of GDM may be at risk of GDM in a future pregnancy, we included women with a history of GDM in the cohort and adjusted for this variable to take into account the confounding related to a history of GDM.

5. As a woman could contribute to the study with repeated pregnancies, and these pregnancies within the same woman may be correlated, we performed an additional analysis using Generalised estimate equation (GEE), which is a method used to address intra-subject correlation. Results obtained from GEE were compared with findings from the main analysis.

6. In the main analysis, women with obesity and overweight were excluded as obesity/overweight can be a potential confounder and/or effect modifier. We performed the same analysis in the subgroup of women with obesity and overweight.

**RESULTS**

In a total of 237172 pregnancies from the QPC meeting the study inclusion criteria, 20905 (8.8%) cases of GDM were identified. This prevalence is concordant with the prevalence reported in Quebec. Among the cases, 1152 (5.5%) women were exposed to ADs (figure 1). The characteristics of the cases and their matched controls (n=209050) are shown in table 1. Women with GDM were more likely to be older urban residents and to benefit from social assistance. Maternal comorbidities and risk factors for GDM were more prevalent in cases than in controls.

**Primary analyses**

When adjusting for potential confounding factors, using ADs during pregnancy was associated with a modest increased risk of GDM compared with non-users during the study period (adjusted OR (aOR) 1.19; 95% CI 1.08 to 1.30, 1152 exposed cases). AD use before 1DG as well as a history of depression and anxiety were not associated with GDM risk (table 2).

For AD classes specifically, SNRI (1.27, 95% CI 1.08 to 1.48, 230 exposed cases), TCA (1.47, 95% CI 1.22 to 1.77, 143 exposed cases) and combined use of $\geq$2 AD classes (1.38, 95% CI 1.15 to 1.67, 169 exposed cases) were associated with an increase in the risk of GDM whereas SSRIs were not (1.07, 95% CI 0.96 to 1.20, 535 exposed cases) (online supplementary table S4).

We also observed a duration-effect gradient associated with gestational AD use. Pregnancies with short duration (1.15, 95% CI 1.03 to 1.28, 541 exposed cases), medium duration (1.17, 95% CI 1.00 to 1.39, 187 exposed cases) and long duration of AD exposure (1.29, 95% CI 1.13 to 1.48, 424 exposed cases) were at increased risk of GDM compared with unexposed pregnancies (online supplementary table S5). This duration-effect relationship was also observed for TCAs, SNRIs and combined use of two AD classes, although it did not reach statistical significance for some strata due to the small number of exposed cases (table 3).

Regarding individual ADs, venlafaxine (1.27, 95% CI 1.09 to 1.49, 230 exposed cases), amitriptyline (1.52, 95% CI 1.25 to 1.84, 133 exposed cases) and combined use of $\geq$2 AD classes (1.31, 95% CI 1.10 to 1.56, 187 exposed cases) were associated with an increased risk of GDM. For citalopram (1.11, 95% CI 0.95 to 1.29, 242 exposed cases), paroxetine (1.13, 95% CI 0.94 to 1.36, 154 exposed cases) and sertraline (1.01, 95% CI 0.80 to 1.28, 83 exposed cases), no statistically significant association was observed (see online supplementary table S6; figure 2).

**Sensitivity analysis**

In the subgroup of 21395 pre-pregnancy depressed women, exposure to ADs during pregnancy also increased the risk of GDM, which is consistent with the main analysis (1.15, 95% CI 1.00 to 1.33, 1002 exposed cases). When using a different time window for both the exposure and the outcome, our results were also consistent
with the main findings as follows: diagnosis between 24 and 28 weeks only (1.22, 95% CI 1.01 to 1.48, 269 exposed cases) and exposure between 1 DG and 15 days before the index date (1.18, 95% CI 1.08 to 1.30, 1139 exposed cases). When including women with a history of GDM and adjusting for this variable in the model, we found similar results to our main analysis (1.11, 95% CI 1.01 to 1.20, 1202 exposed cases). When using the GEE method, which takes into account intra-woman correlation for women contributing to the study with more than one pregnancy, we found similar results to the logistic regression (1.19, 95% CI 1.09 to 1.31). In the subgroup of women with obesity/overweight, we found higher estimates but the result was not statistically significant due to the sample size (1.58, 95% CI 0.84 to 2.98, 32 exposed cases) (see online supplementary table S7–12).

DISCUSSION

In this study, overall AD use was associated with an increased risk for GDM. Specifically, venlafaxine and amitriptyline were associated with a 27% and 52% increased risk of GDM, respectively, after adjustment for major confounders and underlying conditions. No statistically significant association was observed with any SSRI. Moreover, we found a cumulative duration effect for short, medium and long duration of AD use, which was associated with a 15%, 17% and 29% increased risk of having GDM, respectively. This effect varied within classes of ADs.

Comparison with other studies

Literature on this topic is scarce. A previous study by Reis and Källén found that AD is associated with GDM (OR 1.37, 95% CI 1.08 to 1.75), which is consistent with our findings. For class exposure, our results are also in line with those of Wen et al who reported no association between SSRIs and GDM. In the general non-pregnant population, studies and meta-analyses performed to investigate the risk of type 2 diabetes following AD use consistently report associations. Conversely, it is still debated whether SSRIs and SNRIs are involved in type 2 diabetes onset, and very few studies have investigated individual drug effects. A meta-analysis by Yoon et al reported the following estimates for individual drugs: paroxetine (risk ratio (RR) 1.52,
Table 1  Study population characteristics

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Cases of GDM (n=20905)</th>
<th>Controls (n=209050)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pregnancy-related variable</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gestational age at index date*, mean (SD)</td>
<td>29.4 (2.3)</td>
<td>29.4 (2.3)</td>
<td>1.00</td>
</tr>
<tr>
<td>AD exposure from 1DG to index date</td>
<td>1152 (5.5)</td>
<td>8589 (4.1)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>AD use during 6 months before gestation</td>
<td>1448 (6.9)</td>
<td>11 403 (5.4)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td><strong>Sociodemographic characteristics measured on 1DG</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;18</td>
<td>126 (0.6)</td>
<td>2916 (1.4)</td>
<td>–</td>
</tr>
<tr>
<td>18–34</td>
<td>15 123 (72.3)</td>
<td>173 958 (83.2)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>&gt;34</td>
<td>5656 (27.1)</td>
<td>32 176 (15.4)</td>
<td>–</td>
</tr>
<tr>
<td>Urban dwellers</td>
<td>17 678 (84.6)</td>
<td>172 597 (82.6)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Social assistance recipients</td>
<td>5704 (27.3)</td>
<td>48 615 (23.3)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td><strong>Maternal comorbidities during 6 months before 1DG</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Depression/anxiety§</td>
<td>1419 (6.8)</td>
<td>12 995 (6.2)</td>
<td>0.001</td>
</tr>
<tr>
<td>Hypertension</td>
<td>487 (2.3)</td>
<td>2665 (1.3)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Asthma†</td>
<td>1714 (8.2)</td>
<td>14 637 (7.0)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Cardiovascular diseases§</td>
<td>402 (1.9)</td>
<td>3468 (1.7)</td>
<td>0.004</td>
</tr>
<tr>
<td>Thyroid disorders†</td>
<td>930 (4.5)</td>
<td>6354 (3.0)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Polycystic ovarian syndrome§</td>
<td>18 (0.2)</td>
<td>76 (0.1)</td>
<td>0.0007</td>
</tr>
<tr>
<td><strong>Healthcare services utilisation and medication use in the 6 months before 1DG</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No of physician visits</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0–1</td>
<td>10 770 (51.5)</td>
<td>112 674 (53.9)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>≥2</td>
<td>10 135 (48.5)</td>
<td>96 376 (46.1)</td>
<td>–</td>
</tr>
<tr>
<td>Hospital admission/emergency department visit</td>
<td>4278 (20.5)</td>
<td>42 487 (20.3)</td>
<td>0.63</td>
</tr>
<tr>
<td>Medications other than ADs‡</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>9250 (44.2)</td>
<td>95 412 (45.6)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>1–2</td>
<td>4800 (23.0)</td>
<td>46 869 (22.4)</td>
<td>–</td>
</tr>
<tr>
<td>≥3</td>
<td>6855 (32.8)</td>
<td>66 769 (32.0)</td>
<td>–</td>
</tr>
<tr>
<td>At least one visit to psychiatrists</td>
<td>652 (3.1)</td>
<td>5523 (2.6)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td><strong>Healthcare service utilisation from 1DG until index date</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pregnancy follow-up by obstetricians/gynaecologists</td>
<td>9756 (46.7)</td>
<td>77 962 (37.3)</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

*Index date=date of gestational diabetes identification for cases and corresponding date for matched controls.
†Based on ICD-9 or ICD-10 codes or prescriptions filled for hypertension, asthma and thyroid disorders.
‡Included prescriptions filled for conditions other than depression/anxiety, hypertension, asthma and thyroid disorders.
§Based on ICD-9 or ICD-10 codes for depression/anxiety, cardiovascular diseases and polycystic ovarian syndrome.
AD, antidepressant; 1DG, first day of gestation; GDM, gestational diabetes mellitus.

95% CI 0.95 to 2.45, 2 studies) and citalopram (RR 1.13, 95% CI 0.85 to 1.49, 2 studies), which is in line with our results. The relationship between the duration of exposure to ADs and diabetes has been explored in two studies, one in the adult general population and the other in youths. These studies found that the risk of diabetes was increased with a longer duration of use of AD, while taking into account increasing age and weight.42 43 Similarly, we found that women are at higher risk of GDM with increasing age, and that weight gain during pregnancy could possibly and partly explain the risk of GDM.

Possible biological mechanisms

With respect to biological plausibility, certain mechanisms support the link between AD use and GDM onset. ADs can be involved in diabetes by acting directly on glucose homeostasis, 14 by decreasing pancreatic insulin secretion, 44 by increasing cellular insulin resistance 45 or by acting indirectly on insulin via weight gain.13 15

In animal studies it has been reported that ADs can induce hyperglycaemia.45 46 Moreover, serotonin is involved in glucose homeostasis and is also the target of most ADs, which may explain why ADs affect the glucose
pathway. In addition, still in animal studies, serotonin has been shown to play a role in the compensation mechanism, which is established following natural insulin resistance in pregnancy. AD use inhibits the insulin pathway resulting in insulin resistance and potentially GDM. The effects of ADs on glucose dysregulation and weight gain seem stronger with TCAs (especially amitriptyline) than with SNRIs and SSRIs due to the varying affinity for serotonergic, noradrenergic and histamine receptors. A study reported that, due to their high affinity for the serotonin reuptake transporter, SSRIs could generate hypoglycaemia whereas ADs with high affinity for the 5-HT2c receptor (serotonin), H1-receptor (histamine) and norepinephrine reuptake such as amitriptyline and venlafaxine could lead to hyperglycaemia. Moreover, the study added that, among their cases, glucose disturbances were occurring within 1 month of treatment and that cumulative effects of AD drugs on glucose control were possible, especially with a longer duration of treatment.

It has also been proposed that, in the short term, SSRIs may have a neutral weight effect or even reduce weight gain (fluoxetine) and therefore improve diabetes, which could partly explain our results. Our study confirms that ADs have heterogeneous effects regarding GDM incidence, which we believe is mainly due to their varying pharmacological properties.

### Strengths of the study

To our knowledge, this is the first study looking specifically at AD classes and duration of use during pregnancy and the risk of GDM. With 17 years of follow-up, we were able to investigate both class and individual drug effects of ADs. Furthermore, in the QPC, data are prospectively collected and provide valid and accurate information on filled prescriptions and physician-based diagnoses which rule out the potential for recall bias and ascertainment bias. The use of a nested case-control design allows account to be taken of the time-varying nature of our exposure. Finally, our definition of GDM based on diagnoses and prescriptions filled for antidiabetic drugs has been validated and used in previous studies.

### Limitations of the study

Residual confounding by indication related to the underlying depression cannot be ruled out. Our study was not adjusted for depression during pregnancy because depression during pregnancy could be on the causal pathway between AD use and GDM. When we restricted our cohort to a subgroup of pregnancies diagnosed with depression/anxiety before pregnancy, our sensitivity analysis supports our main results. This also minimises the possible detection bias because all pre-pregnancy depressed women might have similar contact with healthcare professionals and an equal chance to be diagnosed for additional comorbidities. Also, since the screening for GDM is part of the standard pregnancy monitoring in Quebec, a detection bias is less likely to occur. To further control for confounding by disease severity, we adjusted for documented proxies for depression severity such as visits to the psychiatrist and co-medication, including medications for mental diseases such as benzodiazepines and antipsychotics.
Table 3  Cumulative duration of exposure to antidepressants and risk of gestational diabetes

<table>
<thead>
<tr>
<th>Exposure status</th>
<th>Cases (n=20905)</th>
<th>Controls (n=209048)</th>
<th>OR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Crude</td>
</tr>
<tr>
<td>No exposure</td>
<td>19753 (94.5)</td>
<td>200461 (95.9)</td>
<td>1.00 (Reference)</td>
</tr>
<tr>
<td>Cumulative duration (d) in days among SSRI users</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;90</td>
<td>242 (1.2)</td>
<td>2047 (0.9)</td>
<td>1.20 (1.05 to 1.37)</td>
</tr>
<tr>
<td>90≤d&lt;180</td>
<td>83 (0.4)</td>
<td>765 (0.4)</td>
<td>1.10 (0.88 to 1.38)</td>
</tr>
<tr>
<td>180≤d</td>
<td>210 (1.0)</td>
<td>1674 (0.8)</td>
<td>1.27 (1.10 to 1.47)</td>
</tr>
<tr>
<td>Cumulative duration (d) in days among SNRI users</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;90</td>
<td>78 (0.4)</td>
<td>718 (0.3)</td>
<td>1.10 (0.88 to 1.39)</td>
</tr>
<tr>
<td>90≤d&lt;180</td>
<td>29 (0.1)</td>
<td>239 (0.1)</td>
<td>1.23 (0.84 to 1.80)</td>
</tr>
<tr>
<td>180≤d</td>
<td>123 (0.6)</td>
<td>707 (0.3)</td>
<td>1.76 (1.45 to 2.13)</td>
</tr>
<tr>
<td>Cumulative duration (d) in days among TCA users</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;90</td>
<td>108 (0.5)</td>
<td>666 (0.3)</td>
<td>1.64 (1.34 to 2.00)</td>
</tr>
<tr>
<td>90≤d&lt;180</td>
<td>21 (0.1)</td>
<td>89 (0.04)</td>
<td>2.39 (1.49 to 3.83)</td>
</tr>
<tr>
<td>180≤d</td>
<td>14 (0.07)</td>
<td>73 (0.03)</td>
<td>1.94 (1.10 to 3.43)</td>
</tr>
<tr>
<td>Cumulative duration (d) in days among users of other antidepressants</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;90</td>
<td>49 (0.2)</td>
<td>440 (0.2)</td>
<td>1.13 (0.84 to 1.52)</td>
</tr>
<tr>
<td>90≤d&lt;180</td>
<td>12 (0.06)</td>
<td>56 (0.03)</td>
<td>2.16 (1.16 to 4.00)</td>
</tr>
<tr>
<td>180≤d</td>
<td>14 (0.07)</td>
<td>103 (0.05)</td>
<td>1.38 (0.79 to 2.41)</td>
</tr>
<tr>
<td>Cumulative duration (d) in days among combined users (users of ≥2 antidepressants)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;90</td>
<td>64 (0.3)</td>
<td>399 (0.2)</td>
<td>1.62 (1.24 to 2.10)</td>
</tr>
<tr>
<td>90≤d&lt;180</td>
<td>42 (0.2)</td>
<td>280 (0.1)</td>
<td>1.52 (1.10 to 2.10)</td>
</tr>
<tr>
<td>180≤d</td>
<td>63 (0.3)</td>
<td>331 (0.2)</td>
<td>1.92 (1.47 to 2.50)</td>
</tr>
</tbody>
</table>

*Adjusted for variables (a) on first day of gestation (maternal age, area of residence (urban vs rural), receipt of social assistance during pregnancy); (b) during 6 months before gestation (physician-based diagnoses or filled prescriptions of related medications for chronic comorbidities (hypertension, asthma and thyroid disorders); physician-based diagnoses of maternal diseases (depression, cardiovascular diseases and polycystic ovarian syndrome); medication use other than antidepressants and drugs for hypertension, asthma and thyroid disorders and visits to psychiatrists); history of antidepressant use and health service utilisation (visits to physicians and hospitalisations or emergency department visits).

We included late cases of GDM recorded after 28 weeks of gestation, which could lead to a misclassification of the exposure and result in an underestimation of the effect. However, when we considered only cases of GDM with a diagnosis between 24 and 28 weeks of gestation, as recommended by the Canadian guidelines, our results were similar to our main analyses. Although we adjusted for most risk factors for GDM, some lifestyle variables such as smoking, weight gain, BMI and physical activity practise are missing in our database, which could result in residual confounding. Previous studies have found inconsistent results for the association between smoking and GDM, but some have shown an association. In a sensitivity analysis, we restricted our cohort to women with depression before pregnancy and found consistent results with the main analysis. This restriction de facto gives us a population of pregnant women with similar characteristics regarding lifestyles such as smoking, alcohol intake and physical activity. We are confident that these missing variables in our analyses would minimally affect our results because Reis and Källén in their study adjusted their analyses for BMI and smoking and found consistent estimates with ours. Family income and education were not directly taken into account in our study. However, women covered by the public prescription drug plan are women of low to middle socioeconomic status. In our analysis, we adjusted for the adherent status with the public prescription drug plan, which is a proxy for the socioeconomic status and education. Adherent women have higher socioeconomic status than beneficiaries. Therefore, by adjusting for adherent status, we also partially adjusted for education. All these sensitivity analyses show that our estimates are stable and that, if residual confounding is present, it is minimal. Moreover, we could not adjust for ethnicity in our study because this variable is not available in our databases. However, a previous study performed on the QPC based on self-administered questionnaires collected information not present in our administrative databases such as ethnicity. This study found that 88.5% of the women in the QPC were from a Caucasian background. Current evidence suggests that women from a Caucasian ethnic background had the lowest risk of GDM.

Figure 2 Types of antidepressant use and risk of gestational diabetes.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Adjusted OR (95% CI)</th>
<th>Forest plot</th>
</tr>
</thead>
<tbody>
<tr>
<td>Citalopram</td>
<td>1.11 (0.95-1.29)</td>
<td></td>
</tr>
<tr>
<td>Fluoxetine</td>
<td>0.85 (0.57-1.25)</td>
<td></td>
</tr>
<tr>
<td>Fluvoxamine</td>
<td>1.01 (0.50-2.03)</td>
<td></td>
</tr>
<tr>
<td>Paroxetine</td>
<td>1.13 (0.94-1.36)</td>
<td></td>
</tr>
<tr>
<td>Sertraline</td>
<td>1.01 (0.80-1.28)</td>
<td></td>
</tr>
<tr>
<td>Venlafaxine</td>
<td>1.27 (1.09-1.49)</td>
<td></td>
</tr>
<tr>
<td>Amitriptyline</td>
<td>1.52 (1.25-1.84)</td>
<td></td>
</tr>
<tr>
<td>Others</td>
<td>1.04 (0.82-1.31)</td>
<td></td>
</tr>
<tr>
<td>Combined use of ≥2 AD</td>
<td>1.31 (1.10-1.56)</td>
<td></td>
</tr>
</tbody>
</table>

Note: CI confidence interval; OR odds ratio; AD Antidepressant;
*Adjusted for variables (a) on first day of gestation (maternal age, area of residence [urban v. rural], receipt of social assistance during pregnancy); (b) During 6 months before gestation (physician-based diagnoses or filled prescriptions of related medications for chronic comorbidities [hypertension, asthma and thyroid disorders]; physician-based diagnoses of maternal diseases [depression, cardiovascular diseases and polycystic ovarian syndrome]; medication use others than antidepressants and drugs use for hypertension, asthma and thyroid disorders and visits to psychiatrists); history of antidepressants use and health services utilization [visits to physicians and hospitalisations or emergency department visit].

Overall, AD use specifically in pregnant women of normal weight was associated with an increased risk of GDM as well as with a cumulative duration effect, after taking into account underlying maternal depression. Amitriptyline and venlafaxine were associated with an increased risk of GDM.

The treatment of depression during pregnancy is a major concern and is challenging because depression is prevalent before and during pregnancy, and untreated depression can lead to relapse during pregnancy and in the postpartum period. Hence, adverse outcomes associated with AD use during pregnancy including GDM should be weighed against the consequences of non-medicated depression, especially for women with severe depression. Further studies are needed to replicate our findings. Results from more studies could translate into changes in clinical practice guidelines. Nevertheless, our findings raise awareness of the risk of GDM with the use of specific ADs during pregnancy.

Contributors All authors participated in the study conception and design. AB acquired the data. MD and OS performed the analyses. MD wrote the manuscript and all authors participated in the interpretation of the results and critical revision of the manuscript. AB is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Funding This study was funded by the Canadian Institutes of Health Research (CIHR) – CAN-AIM grant; Fonds de la recherche du Québec-Santé (FRQ-S) - Réseau de recherche sur les médicaments RQRM-AbbVie. The funding body had no role in the design and conduct of the study; collection, management, analysis and interpretation of the data; preparation, review or approval of the manuscript; or the decision to submit the manuscript for publication.

Competing interests AB has served as a consultant for plaintiffs in litigations involving antidepressants and birth defects. MD and OS report no conflicts of interest; no other financial relationships with any organisations that might have an interest in the submitted work in the previous three years; and no other

compared with other ethnic groups. Thus, our estimates are calculated in a majority Caucasian population and are likely underestimations. This does not affect the internal validity of our study, but might partly limit its generalisability to other ethnic groups. Finally, generalisability to overweight/obese women or women with cystic fibrosis could be affected, given that our study includes only pregnancies of women without cystic fibrosis and non-overweight/non-obese women. Nevertheless, this does not affect the internal validity of our study. Moreover, in a previous study, socioeconomic status was shown to be an effect modifier in the QPC, and those women on the public drug coverage plan and women on private drug insurance have similar characteristics and comorbidities.

Overall, AD use specifically in pregnant women of normal weight was associated with an increased risk of GDM as well as with a cumulative duration effect, after taking into account underlying maternal depression. Amitriptyline and venlafaxine were associated with an increased risk of GDM.

The treatment of depression during pregnancy is a major concern and is challenging because depression is prevalent before and during pregnancy, and untreated depression can lead to relapse during pregnancy and in the postpartum period. Hence, adverse outcomes associated with AD use during pregnancy including GDM should be weighed against the consequences of non-medicated depression, especially for women with severe depression. Further studies are needed to replicate our findings. Results from more studies could translate into changes in clinical practice guidelines. Nevertheless, our findings raise awareness of the risk of GDM with the use of specific ADs during pregnancy.

Contributors All authors participated in the study conception and design. AB acquired the data. MD and OS performed the analyses. MD wrote the manuscript and all authors participated in the interpretation of the results and critical revision of the manuscript. AB is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Funding This study was funded by the Canadian Institutes of Health Research (CIHR) – CAN-AIM grant; Fonds de la recherche du Québec-Santé (FRQ-S) - Réseau de recherche sur les médicaments RQRM-AbbVie. The funding body had no role in the design and conduct of the study; collection, management, analysis and interpretation of the data; preparation, review or approval of the manuscript; or the decision to submit the manuscript for publication.

Competing interests AB has served as a consultant for plaintiffs in litigations involving antidepressants and birth defects. MD and OS report no conflicts of interest; no other financial relationships with any organisations that might have an interest in the submitted work in the previous three years; and no other
Open access

relationships or activities that could appear to have influenced the submitted work.

Patient consent for publication Not required.

Ethics approval The study was approved by the Sainte-Justine’s Hospital Ethics Committee (#1740). The Quebec “Commission d’accès à l’information” authorized database linkages (#2976).

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement No data are available. All data relevant to the study are included in the article or uploaded as supplementary information.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

REFERENCES